» Articles » PMID: 39562334

Interactions of Pain and Opioids on Conditioned Place Preference in Rodents

Overview
Specialty Pharmacology
Date 2024 Nov 19
PMID 39562334
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Opioid analgesics are the most effective medications used for the treatment of pain, however there are significant risks associated with repeated opioid use including opioid misuse and opioid use disorder development. Chronic pain affects millions of adults in the United States, and opioid misuse is often comorbid with pain conditions in individuals who are repeatedly treated with opioids. In addition to providing pain relief, opioids produce rewarding effects, but in chronic pain states, reward processing can become dysregulated. The conditioned place preference task is commonly used to measure the rewarding properties of opioids in rodents. During this task, opioid administration is paired with a distinct environment through repeated conditioning and the change in an animal's preference for the paired environment indicates whether the opioid is rewarding or not.

Objectives: Rodent pain models can be combined with conditioned place preference to examine the effects of pain on opioid reward. The existing preclinical literature on pain effects on conditioned place preference is conflicting, where pain conditions have been reported to enhance, suppress, or have no effect on opioid reward. This review will discuss several factors that may contribute to these discordant findings including conditioning session duration and number, rodent strain differences in opioid sensitivity, analgesic properties of opioids at tested doses, locomotor effects at tested doses, and diurnal variation in pain sensitivity. Future studies should consider how these factors contribute to opioid conditioned place preference in both pain and pain-free animals to have a better understanding of the interactions between pain and opioid reward.

Citing Articles

Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.

Hausenblas H, Hooper S, Lynch T Health Sci Rep. 2025; 8(2):e70481.

PMID: 39980821 PMC: 11839740. DOI: 10.1002/hsr2.70481.

References
1.
Rutten K, De Vry J, Bruckmann W, Tzschentke T . Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur J Pharmacol. 2010; 645(1-3):119-26. DOI: 10.1016/j.ejphar.2010.07.036. View

2.
Kai Y, Li Y, Sun T, Yin W, Mao Y, Li J . A medial prefrontal cortex-nucleus acumens corticotropin-releasing factor circuitry for neuropathic pain-increased susceptibility to opioid reward. Transl Psychiatry. 2018; 8(1):100. PMC: 5960646. DOI: 10.1038/s41398-018-0152-4. View

3.
Peckham E, Traynor J . Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2005; 316(3):1195-201. DOI: 10.1124/jpet.105.094276. View

4.
Edwards S, Callicoatte C, Barattini A, Cucinello-Ragland J, Melain A, Edwards K . Pramipexole treatment attenuates mechanical hypersensitivity in male rats experiencing chronic inflammatory pain. Neuropharmacology. 2022; 208:108976. PMC: 10171400. DOI: 10.1016/j.neuropharm.2022.108976. View

5.
Berge O . Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011; 164(4):1195-206. PMC: 3229757. DOI: 10.1111/j.1476-5381.2011.01300.x. View